Update: Lenacapavir has received Health Canada approval for use as pre-exposure prophylaxis Written by PAN’s Executive Director, J. Evin Jones on April 20th, 2026 On April 14th Gilead Sciences announced that YEYTUO™ (lenacapavir or LEN) has received Health Canada approval for use as pre-exposure prophylaxis (PrEP) for sexually acquired HIV-1 in at-risk adults and adolescents… Read more »
Lenacapavir (LEN) offers new hope in HIV prevention
Posted On: Monday, July 21st, 2025